Open AccessPrephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma
Author(s) -
Richard J. Lin,
Colette Owens,
Esther Drill,
Augustine Iannotta,
Mayan Oliveros,
Dylan L Schick,
Ariela Noy,
John F. Gerecitano,
Pamela Drullinsky,
Philip Caron,
Anita J. Kumar,
Matthew J. Matasar,
Craig H. Moskowitz,
Beatriz KorcGrodzicki,
Andrew D. Zelenetz,
Gilles Salles,
Paul A. Hamlin
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.278719
Subject(s) - medicine , rituximab , prednisone , chemoimmunotherapy , diffuse large b cell lymphoma , hazard ratio , oncology , lymphoma , confidence interval
Diffuse large B-cell lymphoma (DLBCL) predominantly affects older adults with suboptimal therapeutic outcomes due to increased treatment-related mortality and toxicities in vulnerable patients, clinically defined by geriatric impairments such as functional limitation, multimorbidity, or cognitive deficits. In this prospective pilot study, we evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL, defined by either age ≥70 years or age 60-70 years with Karnofsky performance scale (KPS)